New drug combo targets Hard-to-Treat esophageal cancer
NCT ID NCT04921904
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, abemaciclib and ramucirumab, in people with advanced esophageal or gastroesophageal junction cancer that has spread. The goal is to see if this treatment is safe and can help control tumor growth. About 8 participants are enrolled, and the study is no longer recruiting new patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor University Medical Center, Charles A Sammons Cancer Center
Dallas, Texas, 75246, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- Experimental drug combo targets Hard-to-Treat GI cancers
- Supercharged immune cells take on stubborn esophageal cancer
- New drug cocktail shows promise for tough stomach cancers
- New drug cocktail aims to fight Hard-to-Treat stomach cancers
- New combo attack on stomach cancer shows promise in small trial